What is Leerink Partnrs’ Estimate for BPMC FY2025 Earnings?

Blueprint Medicines Co. (NASDAQ:BPMC) – Leerink Partnrs reduced their FY2025 earnings per share (EPS) estimates for Blueprint Medicines in a research note issued on Wednesday, February 5th. Leerink Partnrs analyst A. Berens now forecasts that the biotechnology company will post earnings of ($1.24) per share for the year, down from their prior estimate of ($0.99). The consensus estimate for Blueprint Medicines’ current full-year earnings is ($3.63) per share.

A number of other analysts have also recently weighed in on BPMC. Piper Sandler raised their price target on Blueprint Medicines from $109.00 to $119.00 and gave the company a “neutral” rating in a research note on Monday, January 27th. Stephens reissued an “overweight” rating and set a $140.00 target price on shares of Blueprint Medicines in a research report on Thursday, January 2nd. Wedbush reiterated an “outperform” rating and issued a $124.00 price target (down from $135.00) on shares of Blueprint Medicines in a research note on Monday, January 13th. Needham & Company LLC restated a “buy” rating and issued a $135.00 price objective on shares of Blueprint Medicines in a research note on Monday, January 13th. Finally, Wells Fargo & Company cut their target price on Blueprint Medicines from $153.00 to $151.00 and set an “overweight” rating on the stock in a research report on Thursday, October 31st. One equities research analyst has rated the stock with a sell rating, seven have issued a hold rating, twelve have assigned a buy rating and one has assigned a strong buy rating to the company. According to MarketBeat, the company currently has an average rating of “Moderate Buy” and an average target price of $123.72.

Blueprint Medicines Stock Down 0.9 %

Shares of Blueprint Medicines stock opened at $104.00 on Monday. Blueprint Medicines has a 52-week low of $72.24 and a 52-week high of $121.90. The company has a 50 day moving average of $99.41 and a 200 day moving average of $94.78. The company has a quick ratio of 3.27, a current ratio of 3.32 and a debt-to-equity ratio of 1.09. The company has a market capitalization of $6.61 billion, a P/E ratio of -49.29 and a beta of 0.62.

Insider Buying and Selling

In other news, CEO Kate Haviland sold 2,353 shares of the firm’s stock in a transaction that occurred on Friday, November 29th. The shares were sold at an average price of $96.60, for a total transaction of $227,299.80. Following the completion of the transaction, the chief executive officer now directly owns 150,824 shares of the company’s stock, valued at $14,569,598.40. This trade represents a 1.54 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, COO Christina Rossi sold 2,274 shares of Blueprint Medicines stock in a transaction that occurred on Wednesday, November 27th. The stock was sold at an average price of $95.10, for a total value of $216,257.40. Following the transaction, the chief operating officer now owns 71,657 shares of the company’s stock, valued at $6,814,580.70. This represents a 3.08 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 49,851 shares of company stock valued at $4,984,696. 4.21% of the stock is owned by insiders.

Hedge Funds Weigh In On Blueprint Medicines

Several institutional investors and hedge funds have recently modified their holdings of the company. Wellington Management Group LLP grew its stake in Blueprint Medicines by 22.5% in the 3rd quarter. Wellington Management Group LLP now owns 3,964,610 shares of the biotechnology company’s stock worth $366,726,000 after acquiring an additional 729,055 shares during the period. State Street Corp lifted its holdings in shares of Blueprint Medicines by 16.2% during the 3rd quarter. State Street Corp now owns 2,765,702 shares of the biotechnology company’s stock worth $255,827,000 after acquiring an additional 385,818 shares during the period. William Blair Investment Management LLC boosted its position in shares of Blueprint Medicines by 16.1% in the fourth quarter. William Blair Investment Management LLC now owns 1,944,695 shares of the biotechnology company’s stock worth $169,616,000 after acquiring an additional 269,896 shares during the last quarter. Geode Capital Management LLC increased its position in Blueprint Medicines by 1.4% during the third quarter. Geode Capital Management LLC now owns 1,480,187 shares of the biotechnology company’s stock worth $136,942,000 after purchasing an additional 20,703 shares during the last quarter. Finally, Charles Schwab Investment Management Inc. raised its stake in Blueprint Medicines by 1.2% during the fourth quarter. Charles Schwab Investment Management Inc. now owns 604,397 shares of the biotechnology company’s stock worth $52,716,000 after purchasing an additional 7,165 shares during the period.

About Blueprint Medicines

Blueprint Medicines Corporation, a precision therapy company, develops medicines for genomically defined cancers and blood disorders in the United States and internationally. The company is developing AYVAKIT for the treatment of systemic mastocytosis (SM) and gastrointestinal stromal tumors; BLU-263, an orally available, potent, and KIT inhibitor for the treatment of indolent SM, and other mast cell disorders.